The combination of HDAC inhibitor and chemotherapy exhibited superior efficacy to HDAC inhibitor monotherapy in the R/R PTCL setting. This evidence concerns the gene HDAC9 and mature T-cell and NK-cell non-Hodgkin lymphoma.